[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis].
Adverse cutaneous reactions frequently occur during the treatment of AIDS associated pneumocystosis by trimethoprime-sulfamethoxazole. The most common form is a maculous rash. Treating throughout the duration of hypersensitivity may lead to potentially lethal Stevens-Johnson and Lyell syndromes. Slow acetylator phenotype, a glutathion deficiency and a history of adverse cutaneous reactions have been identified as risk factors of cutaneous reactions. An adjuvant corticosteroid therapy decreases the frequency of adverse cutaneous reactions during the treatment of hypoxaemic pneumocystosis by trimethoprim-sulfamethoxazole.
Caumes
E
E
Service des Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpètrière, Paris.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000890:Anti-Infective Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D015994:Incidence; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D012307:Risk Factors; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced / Q000209:etiology; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects*
D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
Toxidermies au cotrimoxazole et traitement curatif de la pneumocystose du SIDA.